businessbriefs
SubjectsAll subjects on briefs.cloud →
Saved
Companies

AbbVie

2012

AbbVie didn’t win the autoimmune market with science — it won with patents, pricing, and settlements.

Worth your time?4/5Yes.Study the whole thing.What works, what does not, who it is for ↓
10:50in productionCh. 1 · Born from separation/ 10:50 · ceiling 15 min
5 chapters · 10:50Ceiling 15:00

The brief is written and checked. The video joins this page when it is cut.5 chapters · 1 min read · 10:50 planned

Read the brief

AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.

CompaniesPatentsMonopolyPhotographyPatents across the network →
Chapters & takeaways5
  1. 1:21
    Born from separation

    AbbVie exists because Abbott Laboratories spun it off in 2012 — not to launch something new, but to isolate high-margin drugs from slower-growth businesses.

  2. 3:05
    The Humira decade

    Humira dominated for a decade by treating six autoimmune diseases — then lost exclusivity when biosimilars entered in January 2023.

  3. 4:14
    Patent as barrier

    A congressional committee found AbbVie exploited the patent system to extend its monopoly — not an allegation, but a documented finding.

  4. 5:25
    Price of promotion

    AbbVie paid $24 million in 2020 to resolve kickback allegations — proof its commercial tactics crossed legal lines.

  5. 7:06
    The Kaletra misfire

    Its attempt to repurpose Kaletra for COVID-19 failed in the first non-blinded, randomized trial — exposing limits of opportunistic development.

2 more chaptersFewer chapters
Worth your time?

Yes. Study the whole thing.

4/ 5
What works
  • monetising a single molecule across multiple indications
  • extending exclusivity through sequential patents
  • leveraging scale to settle litigation rather than litigate
What does not
  • innovate clinically beyond Humira’s original indication
  • maintain pricing power after biosimilar entry
  • avoid regulatory penalties for commercial conduct
Study it if
  • healthcare investors
  • policy analysts
  • pharma strategists
Skip it if
  • biotech founders seeking R&D inspiration
  • patients evaluating treatment options
Who should study it, and who should skipHide who it is for
The written brief1 min read

What the company or idea is

AbbVie is an American pharmaceutical company formed in 2012 via spin-off from Abbott Laboratories and listed publicly in January 2013.

How it actually makes money

AbbVie makes money primarily from Humira, an injectable autoimmune drug that generated $9 billion in 2024 — 16% of its total revenue.

What works

Humira treats six autoimmune conditions — rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease and ulcerative colitis — and retained market dominance until biosimilar competition began in January 2023.

What does not

Kaletra/Aluvia was not useful to treat severe COVID-19, per a non-blinded, randomized trial.

What to take from it

A company can dominate a therapeutic category for over a decade not by inventing new mechanisms, but by extending monopoly through patents, pricing, and legal settlements — while facing real consequences only when Congress or courts intervene.

Is it worth your time

Yes — as a case study in how patent strategy, regulatory capture, and pricing power shape pharmaceutical profits long after clinical innovation ends.

Same desk · Companies4 of 325
9:50
Russian Railways2003Russian Railways is a textbook case of administrative corporatisation: same assets, same geography, same monopoly, new letterhead. It works as a logistical backbone because the state insists it must — not because it competes, innovates, or balances books.
9:37
Larry Ellison1944Oracle is a database licensing business founded in 1977, renamed twice before adopting the Oracle name in 1983. Its first product launched in 1979 as 'version 2' — no version 1 existed. It nearly failed in 1990, cutting 10% of staff. Its 2010 acquisition of Sun Microsystems required regulatory approval in the U.S. and EU.
10:49
Daiichi Sankyo2005Daiichi Sankyo is a post-merger pharmaceutical entity whose scale derives from consolidation — not innovation velocity. Its revenue is large, its global reach documented, but its growth levers are acquisitions and inherited assets. Its 2015 $39 million kickback settlement signals real regulatory exposure — not just theoretical compliance risk.
11:26
Maruti Suzuki1981Maruti Suzuki is not an Indian automaker that partnered with Japan. It is Suzuki’s Indian subsidiary — created, funded, and de-risked by the Indian state, then handed over intact.
Up next in Business

Abu Dhabi National Oil Company

1971 · 11:08

ADNOC is expanding oil production while the rest of the industry retreats — not because it ignores climate change, but because it answers to no one but Abu Dhabi.

Next brief →Back to Companies
11:08